

Investor Presentation

MISSION:

WE OFFER PEOPLE AROUND THE WORLD A BETTER PATH TO
WELLNESS AND A HEALTHY VIBRANT LIFE.

LifeVantage®



Forward Looking Statements

SAFE HARBOR STATEMENT

This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believe,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “look forward to,” “anticipates” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements are not guarantees of performance and actual results could differ materially from those contained in such statements. These forward-looking statements are based on our current expectations and beliefs concerning future events affecting us and involve known and unknown risks and uncertainties that may cause our actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties are discussed in greater detail in our Annual Report on Form 10-K and Quarterly Report on Form 10-Q under the caption “Risk Factors” and in other documents filed by us from time to time with the Securities and Exchange Commission. We caution you not to place undue reliance on the forward-looking statements contained in this presentation. All forward-looking statements are based on information currently available to us as of today, and we undertake no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

HEALTH CLAIMS DISCLAIMER

Statements made in this presentation and appendices have not been evaluated by the Food and Drug Administration. LifeVantage products are not intended to treat, cure, prevent or mitigate any disease. The statements in this presentation are for investors’ educational purposes only.



LifeVantage Fact Sheet

NASDAQ Ticker	LFVN
Shares outstanding¹	12.4 million
Market Capitalization¹	\$167.0 million
Average Daily Volume¹	104,225
Cash at June 30, 2025	\$20.2 million
Debt at June 30, 2025	Debt free

Share price¹	\$13.46
Float¹	9.9 million
Enterprise Value¹	\$146.8 million
Fiscal 2025 Revenue	\$228.5 million
Fiscal 2025 Adjusted EBITDA²	\$22.1 million
Fiscal 2025 Adjusted EPS²	\$0.82

(1) Source: Factset as of Sept. 4, 2025.

(2) A reconciliation of non-GAAP measures is included in the appendix to this presentation. Fiscal year ends June 30.



LifeVantage At a Glance

- Pioneer in Activation and nutrigenomics with patented, scientifically validated products that work with your unique biology and help your body make what it needs for health
- Direct Sales industry-leader with sales force of independent Consultants and approximately 132,000 active consumers across 20 markets worldwide
- Approximately 70% of total revenues are on monthly subscription
- Highly variable cost structure with minimal capital requirements
- Pristine balance sheet with large and reliable free cash flows
- Fiscal 2025 sales of \$229 million, adjusted EBITDA of \$22 million or 9.7%
- Market cap of approximately \$167 million
- Returned over \$19 million of capital to shareholders since the beginning of fiscal 2024



The Activation Company

ACTIVATING WELLNESS AROUND THE WORLD THROUGH DIRECT SALES

Working in partnership with thousands of Independent Consultants around the world, LifeVantage, the Activation Company, activates many aspects of wellness.

- We ACTIVATE physical wellness, inside and out, with products that help your body make what it needs for health using industry-leading nutrigenomic science. #takeittomakeit
- We ACTIVATE financial, social, and community wellness through direct selling to help a global network of independent Consultants earn extra income in a way that fits their life.


Our mission is to inspire the remarkable through wellness products and entrepreneurial programs that help people feel better and fuel their purpose.




Optimal Position for Direct Sales Industry

ADDRESSING THE TWO LARGEST CATEGORIES IN THE LARGEST MARKETS

Global Sales by Product Category



Top 10 Direct Selling Markets Globally




LIFEVANTAGE OPERATES IN 6 OF THE 10 LARGEST DIRECT SELLING MARKETS GLOBALLY




Activation Around the Globe

LIFEVANTAGE PERCENTAGE OF SALES BY AREA



\$167.7 Billion Industry*



*Source: World Federation of Direct Selling Associations 2023 Data

Note: Company revenue as of the quarter ended 6/30/2025



Acquisition of LoveBiome

- Leader in the emerging microbiome health sector
- Started in 2022
- Driven by a mission to help people live long, healthy meaningful lives through superior and innovative microbiome care.
- Desire to be the most advanced approach to microbiome health on the market led to the development of P84, which launched in March 2025.
- Active Consultant base in US, Taiwan, and Europe

TIMELINE

- September 3 – Acquisition announcement
- October 1 – Expected close, product integration begins (rolling)
- November 1 – Integration into Evolve Compensation Plan





The Activation Approach - Take It To Make It

As the years go by, the toll of time, the environment, and daily choices add up. Most turn to supplements to fill the voids left by modern life. But the truth is, supplements meet basic needs but often fall short when it comes to restoring true health. **With Activation, you #takeittomakeit. We take supplementation a step further, using unique, science-based formulas that unlock your genes to restore optimal cellular function.** This superior approach to wellness works with your biology, empowering your body to make the things (antioxidants, proteins, peptides, hormones, etc.) you need for better health.



TAKE IT

Protandim[®] Nrf2

MAKE IT

Antioxidants

Oxidative stress is a key contributor to the signs of aging, and Protandim Nrf2 Synergizer is the only supplement shown to reduce oxidative stress by 40% in just 30 days. Support your body's own production of powerful antioxidants to fight the signs of aging. **Did you know your own antioxidants are more than 1,000,000X more powerful than any supplement you can take? ***

PATENTED

Several U.S. and international patents, including "Compositions And Methods For Alleviating Inflammation In A Mammal"

SCIENCE BACKED

Studies conducted at the following institutions:

- Ohio State University
- Louisiana State University
- University of Colorado Denver
- Virginia Commonwealth University
- Colorado State University
- Texas Tech University
- Auburn University

PEER-REVIEWED

PUBLISHED RESEARCH

- Free Radical Biology & Medicine
- Enzyme Research
- Circulation
- American Journal of Physiology—Lung Cellular and Molecular Physiology



TAKE IT

Healthy Glow Essentials

MAKE IT

Antioxidants, Collagen

Life is hard on your body. You need **antioxidants** to fight stress, stay balanced and recover. You need **collagen** support because it's crucial and your body stops making enough in your early 20's. Do nothing and let life and aging process take things downhill, or you can take the patent-pending Healthy Glow Essentials Stack.

While Protandim Nrf2 reduces oxidative stress, TrueScience® Liquid Collagen increases collagen density by 100% by activating the body's collagen production, replenishing depleting collagen levels, and maintaining those levels by reducing enzymes that break down collagen.

Together, these products work in tandem to break the cellular stress cycle and restore vital immune function.*



TAKE IT

MindBody GLP-1 System™

MAKE IT

GLP-1

This innovative, patent-pending System is clinically shown to naturally increase GLP-1 by an average of 200% as it balances hunger hormones—no injections or prescriptions required. Build better habits, achieve your ideal weight, and become a stronger, healthier you. [†]^{*}[‡]^Ω

MindBody GLP-1 System™ Benefits

- Naturally increases GLP-1 ^Ω
- Supports sustainable weight loss and wellness for results you can see and feel ^{*‡}
- Helps balance hunger hormones to increase satiety via gut-brain axis, so you feel fuller, longer*
- Quiets “food noise” to cut down cravings and reduce the desire to snack*
- Helps maintain blood sugar levels already within a normal healthy range*



[†] Results may vary. Typical weight loss using this product in a 12-week weight management program is 1–2 pounds per week. This product should be used in conjunction with a healthy diet and regular exercise. Consult with a healthcare provider before starting any weight loss program. ^Ω Results based on a randomized 12-week human clinical study. [◇] MindBody is a dietary supplement and not a replacement for any prescription therapy for a disease.





Transformative, Patent-Pending Results

Key findings from U.S. clinical studies on the MindBody GLP-1 System™ include:

- Over 200% average increase in GLP-1 over 12 weeks^{‡‡}
- Average weight loss of 11 pounds within 12 weeks, with some participants losing up to 25 pounds^{‡,‡‡}
- Up to 9% decrease in total body fat percentage ^{‡,‡‡}
- Up to 24% decrease in visceral fat^{‡,‡‡}
- Up to 9% decrease in subcutaneous fat^{‡,‡‡}
- Up to 6% increase in skeletal muscle^{‡‡}
- 100% of weight lost was from fat, not muscle^{‡,ΩΩ}

In addition to these physical results, participants reported notable changes in their relationship with food:

- 95% reported decreased sugar cravings^{ΩΩ}
- 89% reported decreased fast-food cravings^{§§}
- 86% reported decreased cravings for salt and soda^{§§}
- 85% now eat for health instead of emotions^{ΩΩ}
- 81% reported increased ability to resist snacking^{§§}
- 89% ate less at meals^{§§}
- 86% reported feeling less hungry^{§§}



^{‡‡} Results based on the averaged data of two 12-week randomized human clinical studies. ^{ΩΩ} Results based on a randomized 12-week human clinical study (Study A, N=56). ^{§§} Results based on a randomized 12-week human clinical study (Study B, N=107). [‡] Results may vary. Typical weight loss using this product in a 12-week weight management program is 1–2 pounds per week. This product should be used in conjunction with a healthy diet and regular exercise. Consult with a healthcare provider before starting any weight loss program.




A Natural Approach

What is GLP-1?

GLP-1 (Glucagon-like Peptide – 1) is a hormone produced naturally in the lower GI tract. It regulates appetite and blood sugar levels, while slowing down the rate at which food leaves the stomach. GLP-1 communicates with the brain along the brain-gut axis to promote feelings of fullness or satiety, among other important health benefits. When GLP-1 is at ideal levels in your body, we are less likely to overeat or succumb to cravings. However, genetics, poor diet, and a sedentary lifestyle can lead to low GLP-1 levels in the body

The patent-pending MindBody GLP-1 System™ targets a demographic looking for a natural approach to GLP-1 health benefits. Staying true to the Activation differentiation, this innovative, two-product solution is clinically shown to increase GLP-1 production naturally with a powerful blend of nutrients. This approach works with your body instead of against it, aiming to balance levels of naturally occurring GLP-1.



Understanding the Weight Loss Market

GLP-1 MARKET OVERVIEW

In recent years, drugs including those classified as semiglutides and tirzepatides, have not only changed the approach to diabetes treatments, but obesity and weight management as well. This broad class of drugs work by mimicking hormones that stimulate the release of insulin to increase feelings of fullness and reduce appetite.


- The GLP-1 drug market was valued at USD 19.2 B in 2023.
- The industry is projected to grow from USD 23.2 B in 2024 to USD 88.2 B by 2032, a compound annual growth rate (CAGR) of 21.00%.
- The development of next-generation therapies, increasing prevalence of diabetes and preference for non-insulin therapies are primary drivers for propelling the market growth.

WEIGHT MANAGEMENT IN THE US

Interest in GLP-1 is fueled by a market looking for solutions with **82% of adults currently managing weight.**

The number of US adults (18+) in 2021 = ~260.9 M

- 120 M trying to lose weight
- 73.1 M trying to maintain weight
- 20.8 M trying to gain weight



- I am currently trying to lose weight
- I am currently trying to maintain my weight
- I am currently trying to gain weight
- Not currently managing weight



TAKE IT

LoveBiome™ P84

MAKE IT

Gut Peptides

Your gut plays an essential role. Often referred to as your second brain, it's in constant communication to ensure your entire body is functioning properly. However, your gut gets hit hard with daily attacks from your environment, diet, lifestyle and aging factors. Things can get out of balance – fast.

When it comes to gut health, most people think supplementing their microbiome with pre and probiotics will solve their concerns. But it's confusing to know what you need and supplementation will never address the root issue.

P84 is your easy, all-inclusive, delicious daily antidote to the onslaught, blending naturally derived ingredients that work together to help your body address gut issues at the root source –regulating, repairing and restoring this vital organ from the lining to the microbiome. It's a 3 in 1 approach that takes out all the guesswork, activating your cells so your gut, and health, can thrive – despite the daily onslaught.*

A new, more foundational approach to gut health is here – P84.



Gut Health: A \$32B Market Opportunity Transforming Global Wellness

The gut health market represents one of the most exciting frontiers in wellness and preventive care, with strong momentum and long-term growth potential. Global gut health supplement sales are **projected to reach \$14.4 billion in 2025**, with forecasts indicating an expansion to **\$32.4 billion by 2035**, fueled by a robust CAGR of **8.4%**. This growth is driven by the rapidly increasing recognition of the gut microbiome as a cornerstone of systemic health—impacting immunity, mental well-being, metabolism, and chronic disease prevention. As consumer awareness rises and science continues to validate the central role of gut health, the market is poised for sustained demand, offering investors a compelling opportunity to participate in a category that sits at the intersection of science, consumer lifestyle, and long-term health outcomes.

QUICK STATS

- INDUSTRY VALUE (2025): USD 14,432.0 MILLION
- FORECAST VALUE (2035): USD 32,390.0 MILLION
- FORECAST CAGR: 8.4%
- LEADING SEGMENT IN 2025: PROBIOTIC SUPPLEMENTS (41.2% SHARE)
- KEY GROWTH REGION: NORTH AMERICA, ASIA-PACIFIC, EUROPE



Stacks + Subscriptions for Health Synergies — Inside and Out

We offer several product stacks designed for Subscription. Each provides a unique health solution by delivering activation synergies when the products are used together. Consumers save on products and see and feel even more benefits while Consultants earn more from higher overall consumer spending.

Subscriptions are a proven business strategy to encourage consumers to stay longer and spend more. Recurring Subscription orders account for 70% of monthly revenue.





Modernized Compensation Plan Attracts Independent Business Owners

Our new **Evolve Compensation Plan** helps Consultants activate financial wellness and evolve possibilities in their lives. They can choose to earn supplemental income solely through Customer sales or also by building a team of Consultants. And their Consultant Path clearly progresses through 3 stages: **Share, Build & Grow, and Lead**. A LifeVantage business is flexible, allows people to make a positive difference in the lives of others by sharing products they love, and creates opportunities for growth—personally and professionally.






Accelerating Growth

HISTORY & FOCUS FOR THE FUTURE

Significant Progress with Key Strategic Initiatives

PRODUCT / PLATFORM DEVELOPMENT / CAPITAL ALLOCATION




Laser-Focused on the Experience

Since the launch of LV360 initiatives in 2023, LifeVantage has been laser-focused on increasing active monthly purchasers - enrolling new business builders and Customers, and retaining them longer - by focusing on six elements of our direct sales business – product, social, compensation, consumer experience, community and digital. The key is ensuring every piece of our business fits together to create an excellent experience for everyone.

GUIDING VALUES

- Attract through wellness innovation
- Engage through connections and trust
- Empower each other to achieve the remarkable
- Delight with every experience



Financial Overview



Business Model

LIFEVANTAGE


(as % of revenue)	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Long-term Target
Gross Margin	82.7%	81.5%	79.7%	79.3%	80.4%	80.0%
Commissions and Incentives	47.0%	47.1%	44.4%	42.9%	44.7%	43.0%
SG&A*	26.9%	30.7%	32.9%	31.3%	29.8%	28.0%
Operating Margin*	8.7%	3.7%	2.4%	5.0%	5.8%	9.0%
Adjusted EBITDA Margin*	11.3%	6.2%	5.5%	8.5%	9.7%	12.0%

*A reconciliation of non-GAAP items, including Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings per Diluted Share, is included in the appendix of this presentation.



Revenues

Revenue (USD in thousands)




- FY25 revenue increased 14.2% vs. FY24
- The midpoint of our FY26 revenue guidance of \$225 million to \$240 million represents a 2% increase over FY25



Revenues by Geography

Revenue (USD in thousands)



- Currently selling products in 20 countries
- USA largest market at 78% in FY25
- Japan next largest at 11% in FY24




Strong Balance Sheet

(USD in thousands)	June 30, 2025		June 30, 2024	
Cash and Cash Equivalents	\$	20,201	\$	16,886
Inventory		20,669		15,055
Total Current Assets		50,894		37,646
Total Assets	\$	71,958	\$	60,299
Total Current Liabilities		27,217		22,309
Total Liabilities	\$	37,317	\$	34,308
Total Stockholders Equity		34,641		25,991
Total Liabilities and Stockholders Equity	\$	71,958	\$	60,299



- Debt Free
- \$23.7 MM in working capital at 6/30/25
- Clean Equity – only one class of common shares outstanding
- \$5MM Revolving line of credit available
- \$75MM Shelf Registration in place



Robust Capital Allocation Priorities Deliver...



...Strong Shareholder Returns



Summary

LIFEVANTAGE

- ✦ Well-positioned with on-trend, scientific products in a growing, global sales channel
- ✦ Continuous focus on product innovation, international market expansion, and positive experiences
- ✦ Subscription-based business model with strong cash flow and high incremental margins
- ✦ Modern business model allows Consultants multiple paths to income by rewarding them for selling to Consultants who also want to start a business AND to Customers who prefer to only purchase products.



Appendix



Recent Operating Results Comparison

LIFEVANTAGE

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

	Most Recent Quarter	Prior Year Period	Year over Year Change	Previous Sequential Quarter	Sequential Change
	Q4 of Fiscal 2025	Q4 of Fiscal 2024	%	Q3 of Fiscal 2025	%
Revenue, net	\$ 55,114	\$ 48,931	12.6%	\$ 58,440	(5.7%)
Cost of sales	11,065	10,022		11,113	
Gross profit	44,049	38,909	13.2%	47,327	(6.9%)
Commissions and incentives	23,222	21,979		26,208	
Selling, general and administrative	18,679	14,020		17,066	
Total operating expenses	41,901	35,999		43,274	
Operating income	2,148	2,910	(26.2%)	4,053	47.0%
Interest income, net	111	78		131	
Other expense, net	137	(277)		(4)	
Total other income (expense)	248	(199)		127	
Income before income taxes	2,396	2,711		4,180	
Income tax expense	(437)	(1,406)		(710)	
Net income	1,959	1,305	50.1%	3,470	43.5%
EPS (Net income per share, basic)	\$ 0.16	\$ 0.11	45.5%	\$ 0.28	42.9%
EPS (Net income per share, diluted)	\$ 0.15	\$ 0.10	50.0%	\$ 0.26	42.3%
Weighted-average shares outstanding:					
Weighted average shares, basic	12,236	12,256		12,350	
Weighted average shares, diluted	13,128	12,867		13,300	
Non-GAAP Items					
Adjusted EBITDA*	4,783	4,805	(0.5%)	6,427	(25.6%)
Adjusted Net income *	2,256	1,797	25.5%	3,510	(35.7%)
Adjusted EPS (Net income per share, diluted)*	\$ 0.17	\$ 0.14	21.4%	\$ 0.26	(34.6%)

*A reconciliation of non-GAAP items, including Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings per Diluted Share, is included in the appendix of this presentation.



Historical Income Statements

LIFEVANTAGE

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Fiscal Year ended June 30,

(In thousands, except per share data)

	2023	2024	2025
Revenue, net	\$ 213,398	\$ 200,164	\$ 228,530
Cost of sales	43,387	41,440	44,864
Gross profit	170,011	158,724	183,666
Commissions and incentives	94,687	85,920	102,260
Selling, general and administrative	71,065	68,472	69,207
Total operating expenses	165,752	154,392	171,467
Operating income	4,259	4,332	12,199
Interest income (expense), net	198	430	431
Other expense, net	(458)	(412)	(387)
Total other income (expense), net	(260)	18	44
Income before income taxes	3,999	4,350	12,243
Income tax expense	(1,459)	(1,413)	(2,438)
Net income	2,540	2,937	9,805
EPS (Net income per share, basic)	\$ 0.20	\$ 0.24	\$ 0.80
EPS income (Net per share, diluted)	\$ 0.20	\$ 0.23	\$ 0.75
Weighted-average shares outstanding:			
Weighted average shares, basic	12,557	12,458	12,251
Weighted average shares, diluted	12,567	12,986	12,987
Other comprehensive income (loss), net of tax:			
Non-GAAP Items			
Adjusted EBITDA*	11,721	16,962	22,111
Adjusted Net income *	3,055	7,614	10,649
Adjusted EPS (Net income per share, diluted)*	\$ 0.24	\$ 0.59	\$ 0.82

*A reconciliation of non-GAAP items, including Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings per Diluted Share, is included in the appendix of this presentation.



Historical Balance Sheet and Cash Flows

LIFEVANTAGE

SUMMARIZED BALANCE SHEET AND CASH FLOW METRICS

(Unaudited, in thousands, except per share data)	As of June 30,		
	2023	2024	2025
Cash and Cash Equivalents	\$ 21,605	\$ 16,886	\$ 20,201
Current Portion of Long-term Debt, net	-	-	-
Net Cash (Cash and equivalents less total Debt)	21,605	16,886	20,201
Net Cash per share, diluted	\$ 1.72	\$ 1.30	\$ 1.56
Total Assets	66,123	60,299	72,111
Total Stockholders' Equity	34,649	25,991	34,641
Book Value per share, diluted	\$ 2.76	\$ 2.00	\$ 2.67

(Unaudited, in thousands, except per share data)	Fiscal Year ended June 30,		
	2023	2024	2025
Net Cash Provided by Operating Activities	\$ 6,828	\$ 12,197	\$ 11,878
Capital Expenditures	3,067	2,245	1,371
Free Cash Flow	3,761	9,952	10,507
Free Cash Flow per share, diluted	\$ 0.30	\$ 0.77	\$ 0.81
Free Cash Flow Conversion	148%	339%	107%



Non-GAAP Reconciliations

LIFEVANTAGE

Adjusted Net Income

(Unaudited, in thousands, except per share data)

	Fiscal Year ended June 30,			Three Months ended June 30,	
	2023	2024	2025	2024	2025
GAAP net income	\$ 2,540	\$ 2,937	\$ 9,805	\$ 1,305	\$ 1,959
Adjustments:					
Executive team recruiting and transition expenses	—	198	562	198	38
Executive and non-recurring severance expenses	607	220	244	120	57
Class-action lawsuit expenses, net of recoveries	(139)	—	—	—	—
Nonrecurring proxy contest related expenses, net of credits	—	5,043	—	(118)	—
Accelerated depreciation related to change in lease term	116	—	—	—	—
Lease abandonment	227	—	—	—	—
Other nonrecurring expenses	—	308	248	133	248
Tax impact of adjustments	(296)	(1,092)	(210)	159	(46)
Total adjustments, net of tax	515	4,677	844	492	297
Non-GAAP Net income:	3,055	7,614	10,649	1,797	2,256
Diluted earnings per share, as reported	\$ 0.20	\$ 0.23	\$ 0.75	\$ 0.10	\$ 0.15
Total adjustments, net of tax	0.04	0.36	0.06	0.04	0.02
Diluted earnings per share, as adjusted*	0.24	0.59	0.82	0.23	0.17

*A reconciliation of non-GAAP items, including Adjusted EBITDA, Adjusted Net Income and Adjusted Earnings per Diluted Share, is included in the appendix of this presentation.



Non-GAAP Reconciliations

LIFEVANTAGE

EBITDA and Adjusted EBITDA

(Unaudited, in thousands)

	Fiscal Year ended June 30,			Three Months ended June 30,	
	2023	2024	2025	2024	2025
GAAP net income	\$ 2,540	\$ 2,937	\$ 9,805	\$ 1,305	\$ 1,959
Interest (income) expense	(198)	(430)	(431)	(78)	(111)
Provision for income taxes	1,459	1,413	2,438	1,406	437
Depreciation and amortization	3,579	3,581	3,156	805	750
Non-GAAP EBITDA:	7,380	7,501	14,968	3,438	3,035
Adjustments:					
Stock compensation expense	3,188	3,280	5,702	757	1,542
Other expense, net	458	412	387	277	(137)
Other adjustments	695	5,769	1,054	333	343
Total adjustments	4,341	9,461	7,143	1,367	1,748
Non-GAAP Adjusted EBITDA:	11,721	16,962	22,111	4,805	4,783



Thank you

